EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 6 Issue 1 2024

The Impact of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 2 Diabetes

Apio Christine

School of Nursing Sciences Kampala International University Uganda

ABSTRACT

This scientific review examines the impact of continuous glucose monitoring (CGM) on glycemic control in adults with type 2 diabetes mellitus (T2DM). As the prevalence of T2DM rises globally, effective management strategies are essential to reduce the risk of complications. CGM technology offers real-time glucose data, enhancing patient engagement and self-management. This review highlighted the efficacy of CGM in improving glycemic control, as evidenced by reductions in hemoglobin A1c (HbA1c) levels and decreased hypoglycemic events. Additionally, it discussed patient adherence to CGM, identifying barriers such as discomfort, cost, and the need for comprehensive education. The psychosocial implications of CGM use, including increased confidence and potential anxiety, are also explored. Furthermore, systemic and individual barriers to CGM implementation are examined, alongside future directions for research, including advancements in sensor technology and the integration of artificial intelligence for personalized diabetes management. The methodology employed in this review includes a comprehensive analysis of current literature and clinical studies related to CGM's effectiveness and patient experiences in T2DM management. The findings underscore the transformative potential of CGM in enhancing glycemic control and patient quality of life, advocating for its broader adoption in clinical practice.

Keywords: Continuous Glucose Monitoring (CGM), Type 2 Diabetes Mellitus (T2DM), Glycemic Control, Patient Adherence, Psychosocial Implications.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to chronic hyperglycemia [1, 2]. As global rates of obesity and sedentary lifestyles rise, the incidence of T2DM continues to escalate, imposing a significant burden on healthcare systems worldwide. Effective glycemic control is paramount for minimizing the risk of long-term complications such as cardiovascular disease, neuropathy, retinopathy, and nephropathy, which can significantly impact patients' quality of life and increase healthcare costs. Traditional methods of blood glucose monitoring, such as self-monitoring of blood glucose (SMBG), often involve multiple fingerstick blood tests daily, which can be inconvenient and painful, resulting in inconsistent adherence among patients. Continuous glucose monitoring (CGM) has emerged as a groundbreaking alternative, providing real-time data on glucose levels and trends without the need for frequent fingersticks [3, 4]. CGM systems consist of a small sensor inserted subcutaneously that continuously measures interstitial glucose levels, transmitting data to a display device for easy access. Recent studies indicate that the use of CGM can lead to improved glycemic control in adults with T2DM, evidenced by reductions in hemoglobin A1c (HbA1c) levels, decreased incidence of hypoglycemia, and increased time spent within the target glucose range [5]. Furthermore, CGM empowers patients by facilitating more informed decision-making regarding diet, exercise, and medication management. This review aims to explore the multifaceted impact of continuous glucose monitoring on glycemic control in adults with T2DM, focusing on its efficacy, patient adherence, psychosocial implications, and barriers to implementation, ultimately highlighting the potential of CGM to transform diabetes management.

Overview of Continuous Glucose Monitoring Technology

Continuous glucose monitoring involves the use of a small sensor inserted under the skin that measures interstitial glucose levels continuously, typically every few minutes [6, 7]. These systems transmit data to a display device, providing users with real-time information on glucose trends. Modern CGM systems include

features such as alarms for hypo- and hyperglycemic events, trend arrows indicating the direction of glucose levels, and data sharing capabilities for healthcare providers. Several studies have validated the accuracy and reliability of CGM devices. For example, a meta-analysis indicated that CGM systems have a mean absolute relative difference (MARD) of approximately 9-10%, comparable to traditional SMBG methods. Moreover, technological advancements have led to improvements in sensor accuracy, wearability, and user-friendliness. Patients can now access CGM data via smartphones, enhancing the usability of this technology. The integration of CGM into diabetes management protocols has been shown to enhance patient engagement and facilitate better decision-making regarding insulin dosing and lifestyle modifications. Research indicates that individuals utilizing CGM experience a greater understanding of their glucose patterns, which can lead to improved self-management and more timely interventions when glucose levels deviate from target ranges.

Efficacy of Continuous Glucose Monitoring In Glycemic Control

Numerous clinical trials have demonstrated the efficacy of CGM in improving glycemic control in adults with T2DM [8, 9]. A landmark trial published in the New England Journal of Medicine showed that participants using CGM experienced a significant reduction in hemoglobin A1c (HbA1c) levels compared to those using traditional SMBG. The study indicated an average HbA1c reduction of 0.5% over six months, highlighting CGM's potential as an effective intervention for glycemic management. Furthermore, CGM has been associated with a decrease in the frequency of hypoglycemic events. Hypoglycemia is a common concern for individuals with T2DM, particularly those on insulin or insulin secretagogues. A study published in Diabetes Care demonstrated that CGM users experienced fewer severe hypoglycemic episodes, attributed to real-time glucose monitoring and alarm systems that alerted users before critical glucose levels were reached. This capability is especially important for older adults and individuals with impaired hypoglycemia awareness, as it can prevent adverse events and improve safety. Moreover, CGM has been linked to improved time in range (TIR), which refers to the percentage of time a person's glucose levels remain within a target range. Research indicates that CGM users achieve a higher TIR, which is correlated with better long-term health outcomes. A study examining CGM's impact on TIR reported an increase of approximately 10% in the percentage of time spent within the target glucose range, demonstrating the technology's efficacy in maintaining stable glycemic levels throughout the day [10].

Patient Adherence to Continuous Glucose Monitoring

While CGM shows considerable promise in enhancing glycemic control, patient adherence to the technology remains a significant challenge [11]. Adherence refers to the extent to which patients follow medical advice and use prescribed treatments, which is crucial for the success of any diabetes management strategy. Various factors can influence adherence to CGM, including perceived benefits, ease of use, and psychosocial factors [12]. Research indicates that individuals who perceive CGM as beneficial for their diabetes management are more likely to adhere to its use. A qualitative study highlighted that users appreciated the real-time feedback and the ability to make informed decisions about their diet, physical activity, and insulin dosing [13]. This perceived benefit often translated into sustained usage and greater engagement in self-management practices. However, several barriers can hinder adherence to CGM. One significant barrier is the discomfort associated with sensor insertion and wear. Some users report skin irritation or allergic reactions to the adhesive used in CGM systems, which can deter continued use. Additionally, the cost of CGM devices may be prohibitive for many individuals, particularly in low-income populations or regions with limited healthcare coverage. Education and training are essential for promoting adherence to CGM. Patients must receive adequate instruction on device usage, interpretation of data, and integration of CGM data into their daily routines. Research suggests that structured education programs that include hands-on training and ongoing support can improve adherence rates and overall satisfaction with CGM technology [14].

Psychosocial Implications of Continuous Glucose Monitoring

The introduction of CGM technology also carries significant psychosocial implications for individuals managing T2DM [13, 14]. The ability to access real-time glucose data can empower patients, fostering a sense of control over their condition. Many users report feeling more confident in their ability to manage their diabetes, leading to improved emotional well-being and reduced anxiety related to glycemic fluctuations. However, CGM can also introduce stress and anxiety for some individuals. The constant monitoring of glucose levels may lead to "diabetes distress," where patients feel overwhelmed by the demands of managing their condition. The pressure to achieve optimal glucose levels can create a fear of failure, especially if users experience frequent alarms for hypo- or hyperglycemia [13]. This phenomenon emphasizes the need for comprehensive diabetes education that addresses not only the technical aspects of CGM usage but also the emotional and psychological challenges associated with living with T2DM. Social support plays a critical role in the successful integration of CGM into diabetes management. Studies indicate that individuals who engage in peer support groups or have family members involved in their care experience greater adherence and satisfaction with CGM. Support networks can provide encouragement, share experiences, and help individuals navigate the complexities of diabetes management.

Barriers to Implementation of Continuous Glucose Monitoring

Despite the promising benefits of CGM, several barriers hinder its widespread implementation in clinical practice for adults with T2DM [15, 16]. These barriers can be categorized into financial, systemic, and individual-level challenges. Financial constraints remain a significant obstacle to the adoption of CGM technology. Many health insurance plans may not cover the cost of CGM devices, leaving patients to bear the financial burden. Additionally, the high initial costs associated with purchasing CGM systems can deter patients from adopting this technology, particularly those with limited resources. Policymakers and healthcare providers must advocate for broader insurance coverage and reimbursement models to ensure equitable access to CGM for all individuals with T2DM [16]. Systemic barriers, such as insufficient healthcare provider training and awareness of CGM technology, can also impede implementation. Many healthcare professionals may lack knowledge about the benefits and limitations of CGM, leading to underutilization of this technology in clinical settings. Providing education and training for healthcare providers on the effective use of CGM in diabetes management is crucial to improving patient outcomes. At the individual level, health literacy and technological proficiency can impact a patient's ability to use CGM effectively. Some individuals may struggle to interpret the data provided by CGM or may lack the necessary skills to integrate this information into their diabetes management plans. Tailored educational resources and support programs can help address these barriers and enhance the overall effectiveness of CGM technology in managing T2DM [16].

Future Directions in Continuous Glucose Monitoring Research

As CGM technology continues to evolve, several future directions warrant exploration. Advances in sensor technology, data analytics, and integration with digital health tools can further enhance the efficacy of CGM in managing T2DM [17]. Research is ongoing to develop non-invasive glucose monitoring methods, which may improve patient comfort and adherence to monitoring practices. Moreover, the incorporation of artificial intelligence (AI) and machine learning into CGM data analysis holds promise for personalized diabetes management. AI algorithms can analyze individual glucose patterns, providing tailored recommendations for insulin dosing, dietary adjustments, and physical activity. This personalized approach may lead to improved glycemic control and better overall health outcomes for adults with T2DM. Furthermore, longitudinal studies examining the long-term impact of CGM on glycemic control and diabetes-related complications are essential for establishing the sustained benefits of this technology. Research should also focus on diverse populations, including those with different socioeconomic backgrounds, to understand the barriers and facilitators of CGM adoption in various contexts [17]. Finally, addressing the psychosocial aspects of diabetes management remains critical. Future research should explore interventions that promote mental health and emotional well-being for individuals using CGM. Integrating mental health support into diabetes care can enhance adherence and improve overall health outcomes. In summary, continuous glucose monitoring has emerged as a pivotal technology in the management of type 2 diabetes, demonstrating significant benefits in glycemic control and patient empowerment. As the field continues to evolve, ongoing research and innovation will be essential in maximizing the potential of CGM for improving health outcomes in adults with T2DM.

CONCLUSION

In conclusion, continuous glucose monitoring (CGM) represents a transformative advancement in the management of type 2 diabetes mellitus (T2DM), offering significant improvements in glycemic control and patient empowerment. By providing real-time data on glucose levels, CGM enables users to make informed decisions regarding their diet, exercise, and insulin management, ultimately leading to reductions in hemoglobin A1c levels, fewer hypoglycemic events, and increased time spent within the target glucose range. Despite its advantages, challenges such as adherence, financial barriers, and psychosocial implications must be addressed to maximize the benefits of CGM technology. Education and support are vital for enhancing patient engagement and overcoming hurdles related to device usage and interpretation of data. Future research should focus on advancing CGM technology, integrating artificial intelligence for personalized recommendations, and exploring the long-term impacts of CGM on health outcomes across diverse populations. By addressing these challenges and fostering a holistic approach to diabetes care that includes psychosocial support, the potential of CGM can be fully realized, leading to improved health outcomes and enhanced quality of life for adults living with T2DM.

REFERENCES

1. Lima, J.E.B.F., Moreira, N.C.S., Sakamoto-Hojo, E.T.: Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 874–875, 503437 (2022). https://doi.org/10.1016/j.mrgentox.2021.503437
2. Rachdaoui, N.: Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 21, 1770 (2020). https://doi.org/10.3390/ijms21051770
3. Ahmed, I., Jiang, N., Shao, X., Elsherif, M., Alam, F., Salih, A., Butt, H., K. Yetisen, A.: Recent advances in optical sensors for continuous glucose monitoring. Sensors & Diagnostics. 1, 1098–1125 (2022). https://doi.org/10.1039/D1SD00030F

4. Kazanskiy, N.L., Khonina, S.N., Butt, M.A.: A review on flexible wearables – Recent developments in non-invasive continuous health monitoring. Sensors and Actuators A: Physical. 366, 114993 (2024). https://doi.org/10.1016/j.sna.2023.114993
5. Price, D.A., Deng, Q., Kipnes, M., Beck, S.E.: Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial. Diabetes Ther. 12, 2089–2099 (2021). https://doi.org/10.1007/s13300-021-01086-y
6. Zafar, H., Channa, A., Jeoti, V., & Stojanović, G. M. (2022). Comprehensive review on wearable sweat-glucose sensors for continuous glucose monitoring. *Sensors*, *22*(2), 638.
7. Manasa, G., Mascarenhas, R.J., Shetti, N.P., Malode, S.J., Mishra, A., Basu, S., Aminabhavi, T.M.: Skin Patchable Sensor Surveillance for Continuous Glucose Monitoring. ACS Appl. Bio Mater. 5, 945–970 (2022). https://doi.org/10.1021/acsabm.1c01289
8. Martens, T., Beck, R.W., Bailey, R., Ruedy, K.J., Calhoun, P., Peters, A.L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., Davis, G., Kruger, D., Bhargava, A., Young, L., McGill, J.B., Aleppo, G., Nguyen, Q.T., Orozco, I., Biggs, W., Lucas, K.J., Polonsky, W.H., Buse, J.B., Price, D., Bergenstal, R.M., MOBILE Study Group: Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 325, 2262–2272 (2021). https://doi.org/10.1001/jama.2021.7444
9. Maiorino, M.I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., Esposito, K.: Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care. 43, 1146–1156 (2020). https://doi.org/10.2337/dc19-1459
10. Zoccarato, F., Manzoni, M., Minotti, D., Lettieri, E., Boaretto, A.: Unveiling the interplay between rational, psychological and functional factors in continuous glucose monitoring early adoption: Novel evidence from the Dexcom ONE case in Italy. BMC Health Serv Res. 24, 747 (2024). https://doi.org/10.1186/s12913-024-11195-6
11. Barnard-Kelly, K.D., Martínez-Brocca, M.A., Glatzer, T., Oliver, N.: Identifying the deficiencies of currently available CGM to improve uptake and benefit. Diabetic Medicine. 41, e15338 (2024). https://doi.org/10.1111/dme.15338
12. Smith, M.B., Albanese-O'Neill, A., Macieira, T.G.R., Yao, Y., Abbatematteo, J.M., Lyon, D., Wilkie, D.J., Haller, M.J., Keenan, G.M.: Human Factors Associated with Continuous Glucose Monitor Use in Patients with Diabetes: A Systematic Review. Diabetes Technology & Therapeutics. 21, 589–601 (2019). https://doi.org/10.1089/dia.2019.0136
13. Zoccarato, F., Manzoni, M., Minotti, D., Lettieri, E., Boaretto, A.: Unveiling the interplay between rational, psychological and functional factors in continuous glucose monitoring early adoption: Novel evidence from the Dexcom ONE case in Italy. BMC Health Serv Res. 24, 747 (2024). https://doi.org/10.1186/s12913-024-11195-6
14. Gonder-Frederick, L.A., Shepard, J.A., Grabman, J.H., Ritterband, L.M.: Psychology, technology, and diabetes management. American Psychologist. 71, 577–589 (2016). https://doi.org/10.1037/a0040383
15. Barnard-Kelly, K.D., Martínez-Brocca, M.A., Glatzer, T., Oliver, N.: Identifying the deficiencies of currently available CGM to improve uptake and benefit. Diabetic Medicine. 41, e15338 (2024). https://doi.org/10.1111/dme.15338
16. Hall, T., Warman, M.K., Oser, T., Filippi, M.K., Manning, B., Carroll, J.K., Nease, D.E., Staton, E.W., Oser, S.: Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring. J Am Board Fam Med. 37, 671–679 (2024). https://doi.org/10.3122/jabfm.2024.240049R1
17. Cappon, G., Vettoretti, M., Sparacino, G., Facchinetti, A.: Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J. 43, 383–397 (2019). https://doi.org/10.4093/dmj.2019.0121

CITE AS: Apio Christine (2024). The Impact of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 2 Diabetes. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 6(1):1-4.